JOINTOWN PHARMACEUTICAL GROUP CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.698 CNY | +1.10% |
|
-1.08% | +4.85% |
| Apr. 29 | Jointown Pharma's Q1 Profit, Revenue Fall 4% | MT |
| Apr. 29 | Jointown Pharmaceutical Group's 2023 Profit Jumps 4% | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 26,006 | 33,241 | 26,919 | 24,052 | 26,691 | 27,985 | - | - |
| Enterprise Value (EV) 1 | 28,388 | 36,125 | 29,021 | 21,882 | 24,319 | 23,546 | 24,244 | 21,908 |
| P/E ratio | 15.4 x | 11.7 x | 11.6 x | 12.2 x | 12.7 x | 10.9 x | 9.52 x | 8.29 x |
| Yield | - | 2.75% | 2.04% | 3.83% | 3.57% | 4.5% | 5.15% | 6.43% |
| Capitalization / Revenue | 0.26 x | 0.3 x | 0.22 x | 0.17 x | 0.18 x | 0.17 x | 0.15 x | 0.13 x |
| EV / Revenue | 0.29 x | 0.33 x | 0.24 x | 0.16 x | 0.16 x | 0.14 x | 0.13 x | 0.1 x |
| EV / EBITDA | 10 x | 7.36 x | 6.93 x | 6.21 x | 6.5 x | 4.24 x | 3.99 x | 3.1 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 1.42 x | 1.75 x | 1.31 x | 1.09 x | 1.14 x | 1.18 x | 1.07 x | 1.03 x |
| Nbr of stocks (in thousands) | 4,945,666 | 4,925,621 | 4,921,006 | 4,963,416 | 4,911,693 | 4,911,693 | - | - |
| Reference price 2 | 5.258 | 6.749 | 5.470 | 4.846 | 5.434 | 5.698 | 5.698 | 5.698 |
| Announcement Date | 4/28/20 | 4/26/21 | 4/25/22 | 4/24/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 99,497 | 110,860 | 122,407 | 140,424 | 150,140 | 168,312 | 189,211 | 208,908 |
| EBITDA 1 | 2,838 | 4,909 | 4,187 | 3,526 | 3,741 | 5,559 | 6,079 | 7,065 |
| EBIT 1 | 2,301 | 4,352 | 3,593 | 2,853 | 3,023 | 4,209 | 4,752 | 5,835 |
| Operating Margin | 2.31% | 3.93% | 2.93% | 2.03% | 2.01% | 2.5% | 2.51% | 2.79% |
| Earnings before Tax (EBT) 1 | 2,317 | 4,334 | 3,363 | 2,838 | 2,991 | 3,764 | 4,305 | 5,118 |
| Net income 1 | 1,727 | 3,075 | 2,448 | 2,085 | 2,174 | 2,759 | 3,160 | 3,750 |
| Net margin | 1.74% | 2.77% | 2% | 1.48% | 1.45% | 1.64% | 1.67% | 1.8% |
| EPS 2 | 0.3419 | 0.5760 | 0.4720 | 0.3976 | 0.4264 | 0.5246 | 0.5988 | 0.6876 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.1858 | 0.1115 | 0.1858 | 0.1938 | 0.2565 | 0.2933 | 0.3663 |
| Announcement Date | 4/28/20 | 4/26/21 | 4/25/22 | 4/24/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 35,776 | 40,472 | 40,389 | 43,755 | 43,671 | 37,515 | 45,018 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | 1,346 | 1,444 | 1,544 | 1,330 | 1,552 |
| EBIT 1 | - | - | - | - | - | - | - | 614.6 | 665.4 | 1,179 | 1,277 | 1,378 | 1,109 | 1,331 |
| Operating Margin | - | - | - | - | - | - | - | 1.72% | 1.64% | 2.92% | 2.92% | 3.15% | 2.96% | 2.96% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | - | - | 618.7 | 661.8 | 978 | 1,059 | 1,376 | 937.1 | 1,124 |
| Net income 1 | - | - | - | - | - | - | - | 350.4 | 537.7 | 744.3 | 806.3 | 1,013 | 713.1 | 855.8 |
| Net margin | - | - | - | - | - | - | - | 0.98% | 1.33% | 1.84% | 1.84% | 2.32% | 1.9% | 1.9% |
| EPS 2 | 0.0149 | 0.0855 | 0.1598 | 0.0892 | 0.0632 | 0.1078 | 0.1550 | - | 0.1085 | 0.1591 | 0.1536 | 0.1741 | 0.1414 | 0.1697 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | 0.3508 | - | - | - | 0.3992 |
| Announcement Date | 4/25/22 | 4/25/22 | 8/22/22 | 10/24/22 | 4/24/23 | 4/24/23 | 8/28/23 | 4/26/24 | 4/27/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 2,381 | 2,884 | 2,102 | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 2,170 | 2,372 | 4,439 | 3,742 | 6,077 |
| Leverage (Debt/EBITDA) | 0.8391 x | 0.5876 x | 0.5021 x | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 9.32% | 15.9% | 11.4% | 8.98% | 9.04% | 10.8% | 11.4% | 12.7% |
| ROA (Net income/ Total Assets) | 2.51% | 4.05% | 2.94% | 2.34% | - | 2.6% | 2.75% | - |
| Assets 1 | 68,924 | 75,984 | 83,379 | 89,104 | - | 106,129 | 114,912 | - |
| Book Value Per Share 2 | 3.710 | 3.850 | 4.160 | 4.450 | 4.760 | 4.830 | 5.350 | 5.520 |
| Cash Flow per Share 2 | 0.5500 | 0.6800 | 0.6900 | 0.7900 | 0.9400 | -1.670 | 1.070 | -0.0800 |
| Capex 1 | 1,175 | 1,158 | 1,215 | 1,083 | 885 | 1,165 | 1,201 | 1,468 |
| Capex / Sales | 1.18% | 1.04% | 0.99% | 0.77% | 0.59% | 0.69% | 0.63% | 0.7% |
| Announcement Date | 4/28/20 | 4/26/21 | 4/25/22 | 4/24/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
5.698
CNY
Average target price
7.857
CNY
Spread / Average Target
+37.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.85% | 3.82B | |
| +26.60% | 75.34B | |
| -1.98% | 23.86B | |
| +10.51% | 8.61B | |
| +10.22% | 8.52B | |
| -22.96% | 7.78B | |
| +12.33% | 5.18B | |
| +2.96% | 4.13B | |
| -5.61% | 4.03B | |
| +0.88% | 3.09B |
- Stock Market
- Equities
- 600998 Stock
- Financials Jointown Pharmaceutical Group Co., Ltd
